Skip to main content
. 2021 Nov;33(4):320–322. doi: 10.1177/10848223211035718

Table 1.

Demographic Data for All Patients Treated with Remdesivir.

Total (n = 39)
Age years (mean ± SD) 62.3 ± 13.2
Male, n (%) 21 (54)
Race, n (%)
 Asian 4 (10)
 Black 3 (8)
 White 26 (67)
 Other/unknown 6 (15)
Comorbidities, n (%)
 Obesity (BMI > 30 kg/m2) 8 (21)
 Hypertension 17 (44)
 Diabetes 5 (13)
 Any comorbidity 21 (54)
Time from diagnosis to treatment, days, mean (SD) 7.4 ± 3.8
Total remdesivir doses, median (IQR) 5 (2-5)
Other therapies, n (%)
 Oxygen 29 (74)
 Glucocorticoids* 33 (85)
 Monoclonal antibody 10 (26)
 Prophylactic anticoagulation 14 (36)
*

Glucocorticoids include both dexamethasone and prednisone.

Prophylactic anticoagulation includes both rivaroxaban and apixaban.